The Effect of Human Immunoglobulin Combined with Meropenem Treatment on Symptom Improvement Time and Immune Function Indicators in Neonatal Sepsis Patients
Objective Exploring the effect of human immunoglobulin combined with meropenem therapy on neonatal sepsis.Methods Selecting 60 cases of neonatal sepsis admitted to our hospital from August 2022 to August 2023 as the research subjects,divided into a control group and an observation group using a random number table method,with 30 cases in each group.The control group received treatment with meropenem,the observation group treated with human immunoglobulin combined with meropenem,both groups received continuous treatment for 10 days.The immune function indicators,clinical efficacy,time to symptom improvement,and inflammatory factor levels were compared between the two groups.Results After treatment,the total clinical effective rate of the observation group was higher than that of the control group,the difference between groups was statistically significant(P﹤0.05);the improvement time of body temperature,rejection of milk,neurological symptoms,as well as the time for blood culture to turn negative and hospital stay in the observation group were shorter than those in the control group,the differences between groups were statistically significant(P﹤0.05);The levels of immunoglobulin A,immunoglobulin G,and immunoglobulin M in the observation group were all higher than those in the control group,the levels of interleukin-6,C-reactive protein,and tumor necrosis factor-α were also higher than those in the observation group,the differences between groups were statistically significant(P﹤0.05).Conclusion In neonatal sepsis,human immunoglobulin combined with meropenem treatment can accelerate the improvement of clinical symptoms,reduce inflammation,and regulate immune indicators.
Neonatal sepsisHuman immunoglobulinMeropenemSymptom improvement timeImmune function indicatorsLevel of inflammatory factors
NETL
NSTL
万方数据
